Effectiveness and safety of HIV post-exposure prophylaxis after sexual, injecting-drug-use or other non-occupational exposure

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 2, 2018, Pages

  Martin, Nuria V ^a   Casabona, Jordi ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTED ARTICLE;

EID: 85041955057     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005273.pub2     Document Type: Article

References (21)

1. Almeda J, Simon BG, Casabona J, Rey D, Allepuz A, Puro V, et al. Knowledge, attitudes and practices of physicians regarding non-occupational post-exposure prohpylaxis (NONOPEP) for HIV. (Abstract: WePeC6146 in abstract book, Volume 2, pag.118). Fourteenth International Conference on AIDS. Barcelona, 7-12 July 2002. 2002.
2. Black RJ. Animal studies of prophylaxis. Am J Med. 1997; 102(5B): 39-44 1997.
3. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337(21): 1485-90. 1997.
4. Centers for Disease Control and Prevention (United States). Public Health Service. Guidelines for management of Health Care Workers exposure to HIV and recommendations for Post Exposure Prophylaxis. Morb Mortal Wkly Rep 1998; 47(RR-7): 1-28. 1998.
5. Centers for Disease Control and Prevention (United States). Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Morb Mortal Wkly Rep 1998; 47(RR-17): 1-33. 1998.
6. Centers for Disease Control and Prevention (United States). Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Morb Mortal Wkly Rep 1998; 47(RR-17): 1-14. 1998.
7. Centers for Disease Control and Prevention (United States). Updated US Public Health Service Guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for Post Exposure Prophylaxis. Morb Mortal Wkly Rep 2001; 50(RR-11): 1-67. 2001.
8. Centers for Disease Control and Prevention (United States). Guidelines for treatment of sexually transmitted diseases. Morb Mortal Wkly Rep 2002; 51 (RR-6): 1-84 2002.
9. Connor EM, Sperling RS, Gelberg R, Kiselev P, Scott G, O'Sullivan MJ, et al. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type with zidovudine treatment. N Engl J Med 1994; 331(18): 1173-80. 1994.
10. Dilly JW, Woods WJ, McFarland W. Are advances in treatment changing views about high-risk sex? [Letter]. Ann Intern Med 1996; 124: 855. 1996.
11. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicianś experiences and attitudes. AIDS 2002 (England); 16: 397-405. 2002.
12. Ministère de ĺemploi et de la solidarité. [Circulaire DGS/DH/DRT/DSS no98/228 du 9 avril 1998 relative aux recommandations de mise en oeuvre dun traitement antiretroviral après au risqué de transmission du VIH.]. Paris: Ministère de ĺEmploi et de la Solidarité; 1998. 1998.
13. Ministerio della Sanità da Italia. [Comissione Nazionale per la lotta contro ĺAIDS e le malattie infettive emergenti e riemergenti. Aggiornamento delle Linee-guida per la chemioprofilassi con antiretrovirali dopo esposixione occupazionale ad HIV negli operatori sanitari.]. Ministerio della Sanità da Italia, Giornale Italiano delle Infezioni Ospedaliere 1997; 4 1997.
14. Office federal de la santé publique. [Recommendations préliminaires pour la prophylaxie postexposition du VIH hors environnement medical.]. Bulletin 1997; 50: 4-7. 1997.
15. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74(20): 9771-5. 2000.
16. Pinkerton SD, Steven D, Holtgrave DR, Bloom FR. Cost-effectiveness of chemophylaxis following sexual exposure to HIV. AIDS 1998; 12(9): 1067-78. 1998.
17. Puro V, Hipólito G. [Le pillole del giorno dopo. Consideración sulla di una profilassi farmacológica delĺinfeziones da HIV per le esposizioni non occupazionali.]. Giornale Italiano delĺAIDS 1998; 9: 29-32. 1998.
18. Saag MS. Candidate antiretroviral agents for use in post exposure prophylaxis. Am J Med 1997; 102: 25-31. 1997.
19. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. NEJM 1996; 335: 1621-9. 1996.
20. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183: 215-25. 1996.
21. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of post inoculation R-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIV infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72(5): 4262-73. 1998.